cyrilzakka/clinical-trials huggingface dataset:
Interest of Hypnosis on Pain Management During a Guided Echo Infiltration of the Hand

Ultrasound-guided infiltration is a common procedure and is known to be locally painful. This care-induced pain leads to strong apprehension in patients who need to benefit from this procedure.

The practice of hypnosis to improve the patient's comfort during a treatment has appeared progressively in hospital departments.

Among the various existing conversational hypnosis techniques, there is the "magic glove" technique. This is the technique that will be used in this study.

The investigators wish to evaluate the interest of hypnosis on the pain felt by the patient when performing an echo-guided infiltration of the hand, one of the most painful extremities during infiltrations.


Eligibility Criteria:
Inclusion Criteria:

* Patient with an indication of a first hand infiltration under ultrasound examination
* Major patient
* Patient with capacity to understand the protocol and has given oral consent to participate in the research,
* Patient with social security coverage.

Exclusion Criteria:

* Patient having preventively applied a pain patch to the area to be infiltrated
* Contraindication to infiltrations ( imbalanced diabetes, imbalanced,hypertension, ongoing infections).
* Hearing impaired patient
* Patient under guardianship/curtel
* Minor
* Pregnant woman
* Patient participating in another intervention research protocol
* Patient unable to follow the protocol as judged by the investigator.
Effects of Pain on Driving Performance and Cognition.

It has been suggested that cognitive functioning is impaired in chronic pain patients. Since most of these pain patients engage in daily activities including driving, it was hypothezised that they may have an increased risk of becoming involved in traffic accidents.

Most chronic pain patients engage in daily activities including driving. Driving a car is a complex task requiring mental alertness and a variety of cognitive functions such as perception, attention, learning, memory and decision making.Several studies have demonstrated cognitive impairments on laboratory tasks in patients with chronic pain, particularly on measures assessing attentional capacity, processing speed and psychomotor speed. These findings suggest that car driving performance might be impaired, and that chronic pain patients may therefore have an increased traffic accident risk. Unfortunately, no studies have investigated the impact of chronic pain on actual driving ability. The present study was designed to investigate the effects of chronic pain on actual driving performance during normal traffic. In addition to the on-the-road driving test, psychomotor, and memory tests measuring driving-related skills were conducted in the laboratory. Moreover, effects of pain on an attentional capacity test were tested using event-related potentials.

Eligibility Criteria:
Inclusion Criteria:

age driving licence driving experience normal vision right-handed fluently Dutch speaking

Exclusion Criteria:

psychological or physical disorder drug or alcohol abuse psychotropic medication use excessive smoking, drinking
Long-term Study Of Paroxetine in Women and Men

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)


Eligibility Criteria:
Inclusion criteria:

* Diagnosis of Social Anxiety Disorder (SAD) (300.23 Social Phobia/Social Anxiety Disorder) according to DSM-IV-TR criteria.
* Must give a written informed consent.
* If the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent.
* Patients have a minimum score of 60 on the LSAS total score.

Exclusion criteria:

* Patients primarily diagnosed with a disorder that is categorized into Axis I excluding SAD by DSM-IV-TR (e.g. major depression, dysthymic disorder, specific phobia (simple phobia) , obsessive compulsive disorder, panic disorder) within 24 weeks before week -2.
* Patients with a history or complication of schizophrenia and bipolar disorder
* Patients with a complication of body dysmorphic disorder.
* Patients with evidence of substance abuse (alcohol or drugs).
* substance dependence by DSM-IV-TR criteria within 24 weeks before week -2.
* Patients who started psychotherapy and cognitive-behavioural therapy within 24 weeks before week-2, except for supportive psychotherapy.
* Patients receiving electro-convulsive therapy (ECT) within 12 weeks before week -2.
* Patients being pregnant, lactating or are of childbearing potential and are likely to become pregnant.
* Patients with 3 or more points of HAM-D Item No. 3, or who are likely to attempt suicide.
* Patients with a history or complication of cancer or malignant tumor.
* Patients receiving MAO inhibitors (FP®) within 14 days before expected week 0 visit date.
Prevention of Weight Gain

The purpose of this study is to test methods for preventing weight gain in normal-weight and overweight women aged 25 through 44. Participants will complete brief questionnaires about their health, eating and exercise habits, and use of weight control strategies. They will then be randomly assigned to 1 of 3 treatment conditions. All 3 treatments receive information on the importance of maintaining a healthy body weight, the components of a healthy diet, and ways to increase activity levels. The 3 treatment differ in how this information is delivered. At 12, 24 and 36 months after enrolling in the study, participants will attend assessment sessions. They will complete questionnaires and have body weight measured.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index of 21 through 30

Exclusion Criteria:

* Presence of chronic disease that precludes regular physical activity or changes in dietary intake
* Currently receiving treatment for psychological disorder
* Currently pregnant or having given birth within last 12 months
* Use in last 3 months of weight loss medications or other drugs that affect body weight
* Participation in a weight loss program in last 12 months
* Planning to relocate outside the study area in the next 3 years
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC

Phase II clinical study of AK112, an anti-PD-1 and VEGF bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer

Eligibility Criteria:
Inclusion Criteria:

1、18 to 75 years old

2、Be able and willing to provide written informed consent and to comply with all requirements of study participation

3、Histologically confirmed resectable stage II-IIIB NSCLC

4、Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

5、Has adequate organ function

6、All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.

Exclusion Criteria:

1. Is currently participating in a study of an investigational agent or using an investigational device
2. Has an active autoimmune disease that has required systemic treatment in the past 2 years
3. Has an active infection requiring systemic therapy
4. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected)
5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
6. Has received a live virus vaccine within 30 days prior to first dose of study treatment
7. Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.
Faecal Microbiota Transplantation for Microscopic Colitis

A pilot study investigating if orally administrated faecal microbiota transplantation capsules have the potential to treat active microscopic colitis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of microscopic colitis
* Date of diagnosis/histological confirmation \< 12 months
* Active disease according to Hjortswang's criteria

Exclusion Criteria:

* Diagnosed with ulcerative colitis or Crohn's disease
* Diagnosed with celiac disease
* Active gastrointestinal infection
* Previous bowel resection of bowel (except appendectomy)
* Previous cholecystectomy
* Treatment with systemic steroid within 4 weeks, including budesonide
* Antibiotics 3 months prior
* Severe immunodeficiency,
* Pregnancy, planned pregnancy and breastfeeding
* Treatment with constipants such as psyllium, loperamide, bile binders, opium drops or codeine up to 2 weeks before inclusion and during participation
Effect of Tea Tree Oil and Coconut Oil on Nipple Crack Formation

The aim of the study was to determine the effect of tea tree oil and coconut oil applied to the nipples during the early postpartum period on nipple crack formation.

This randomized controlled experimental research included a total of 90 women in the research sample abiding by the research criteria, with 30 each in the intervention groups (coconut oil or tea tree oil application) and 30 in the control group. Women in the intervention groups applied coconut oil or tea tree oil to the nipples on the 3rd, 7th and 10th days postpartum, while the control group did not have any intervention

Eligibility Criteria:
Inclusion Criteria:

* Mothers who volunteered for participation, h
* aged from 18-45 years,
* with new and live birth after 37 weeks,
* without flat or small nipple problems,
* without previous breast operations,
* able to apply correct breastfeeding methods and with infants with birth weight of 2500 g and above were included in the study.

Exclusion Criteria:

* Mothers who could not breastfeed,
* had stillbirth,
* who had infants with congenital anomalies preventing breastfeeding were not included in the study.
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients

Our central hypothesis is that patient response to treatment, evaluated by full spectrum of outcome measures including tumor control, survival, toxicity, and quality of life (QoL), will correlate with biomarker expressions, which can be tested in the blood, other body fluid, imaging as well as tumor tissue (if available).

The primary biomarkers of our interest are those obtained from minimally invasive procedures and those associated with immune/inflammatory treatment responses such as lymphocyte count, immune cell subtype distribution, TGF-beta1, immunomodulating interleukins and IDO metabolites. We will measure the biomarkers pre-, during- and post-anticancer treatment for hypothesis driven studies, and bank residual biological specimen, in combination with prospectively collected data including patient/tumor/treatment factors, imaging, tumor control outcome, treatment toxicity and QOL measures. We will classify the tumor response according to RECIST criteria and qualify QoL by using the PROMIS grading system and correlate them with the corresponding biomarkers. This study will serve young investigators who are interested in biomarker studies for early diagnosis, tumor control outcome and treatment toxicity/QOL prediction, aiming to guide personalized cancer care in future.

Eligibility Criteria:
Inclusion Criteria:

Cancer Patients

* 18 years of age and older.
* Scheduled to receive any kind of therapy in our center.
* Performance status of ECOG 0, 1, 2, or 3.
* Able to understand QoL questionnaire.

Normal (non cancer) controls

* 18 years of age and older healthy volunteers.
* Without a history of cancer except for cured skin cancer, without any active cancer.
* ECOG Performance status 0, 1, 2, or 3.

Exclusion Criteria:

Participants who have supposedly limited ability to complete the survey questionnaires of the present study will be excluded.
Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology

Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.

Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.

Eligibility Criteria:
Inclusion Criteria:

1. Patient with cervical cancer, at any stage, before any anti-tumoral treatment.
2. Age ≥ 18 years.
3. Patient information and signature of the informed consent or her/his legal representative.
4. Patient having given her/his agreement for a second biopsy at diagnosis if the first one was performed outside of the center and was not cryopreserved.

Exclusion Criteria:

1. Person deprived of liberty or under supervision.
2. Inability to attend scheduled follow-up visits for any psychological, sociological or geographical reasons.
OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension

Longitudinal clinical observation of optic nerve head, using slit lamp fundoscopy, guides therapy in pediatric idiopathic intracranial hypertension (IIH) patients; however, it remains a limited method of producing quantitative data in evaluating in patients with IIH.

In this study we intend to compare, by using spectral domain optical coherence tomography (OCT), the mean retinal nerve fiber layer thickness and total retinal thickness (RNFLT/TRT) of the optic nerve of newly diagnosed IIH children to a control group. This will provide a quantitative measure for follow-up and treatment of this patient group.


Eligibility Criteria:
Inclusion Criteria:

* Children with suspected IIH

Exclusion Criteria:

* Retinal disease
* High refractive error
* Unable to undergo OCT imaging
Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development

The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly chemotherapy in genetically susceptible patients.


Eligibility Criteria:
Inclusion Criteria:

* Participants must be at least 18 years of age
* Participants must have been clinically diagnosed with breast cancer and scheduled for axillary lymph node dissection (ALND) and radiation treatment at MD Anderson (receiving chemotherapy, mastectomy or breast-conserving surgery, ALND (\>10 nodes) and radiation treatment for breast cancer, identified by Drs. Mittendorf and Shaitelman of the Nellie B. Connally Breast Cancer Center at MD Anderson)
* Ambulatory and possessing all four limbs
* No prior radiation therapy
* Negative urine pregnancy test within 36 hours prior to study drug administration, if of childbearing potential
* Females participants must complete the Female Enrollment Form. Childbearing potential participants must agree to use one of the medically accepted forms of contraception for a period of one month after study participation. Female participants who meet the criteria for non-childbearing will still complete the Female Enrollment Form, but are not restricted to the use of contraception following study participation.

Exclusion Criteria:

* Participants with a known or suspected allergy to iodine
* Participants who are breastfeeding, pregnant or trying to become pregnant
* Severe underlying chronic illness or disease (other than breast cancer)
* Participants not capable of keeping moderately still for the imaging portion of the study session (\~1 hour for imaging)
Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers

The purpose of this study is to determine whether an innovative preventive strategy, consisting of early salpingectomy upon completion of childbearing with delayed oophorectomy beyond current guideline age, improves menopause-related quality of life without significantly increasing ovarian cancer incidence in comparison to current standard salpingo-oophorectomy in female BRCA1/2 mutation carriers.

Eligible women will choose for the innovative or standard risk-reducing option themselves.

Eligibility Criteria:
Inclusion Criteria:

* Premenopausal women with a documented BRCA1 and/or BRCA2 germline mutation
* Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2
* Childbearing completed
* Presence of at least one fallopian tube
* Participants may have a personal history of non-ovarian malignancy

Exclusion Criteria:

* Postmenopausal status (natural menopause or due to (cancer) treatment)
* Wish for second stage oophorectomy within two years after salpingectomy (if clear at enrollment)
* Legally incapable
* Prior bilateral salpingectomy
* A personal history of ovarian, fallopian tube or peritoneal cancer
* Evidence of malignant disease at enrollment
* Treatment for malignant disease at enrollment
* Inability to read or speak Dutch

BRCA mutation carriers who opt for salpingectomy but who do not want to postpone the oophorectomy beyond the guideline age will undergo similar follow-up but do not contribute to the 510 inclusions we need
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)

This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.

This is an in vitro evaluation of cutaneous T-cell lymphoma using patients blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/ CD 8 cells with the following objectives:

* Objective I: Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL) undergoing an approved FDA therapy, extracorporeal photopheresis (ECP).
* Objective II: Evaluate antigen loading of the DCs.
* Objective III: Test the functional capacities of the DCs derived from CTCL subjects to overcome immune tolerance to the tumor cells ex-vivo, by using modified Elispot assay in conjunction with Granzyme B Elispot assay as a measurement of cytotoxicity.

Eligibility Criteria:
Inclusion Criteria:

* Males or females \<18 years of age
* Histologically confirmed stage IV cutaneous T-cell lymphoma, with at least 5% of the peripheral blood lymphocytes showing atypical morphology consistent with Sezary cells
* Ambulatory and be in stable medical condition
* Biopsy positive mycosis fungoides/CTCL or clonal type of CTCL as determined by PCR for TCR and Southern blot for TCR

Exclusion Criteria:

* Received any chemotherapy or radiotherapy within 4 weeks prior to enrollment
* Significant psychiatric illness which would prevent adequate informed consent in the opinion of the principal investigator
* Systemic steroid therapy other than maintenance for adrenal suppression
* Known coagulopathy for non SS subjects.
Cabergoline as a Preventive Treatment for Chronic Migraine

Headache disorders constitute a major global disease burden, and migraine - with a one-year prevalence of 15 % - is the sixth most disabling condition. Though a common disease, the pathogenesis is still unclear. Thus, the treatments have different mechanisms of action and preventive treatments are only effective in approximately 50% of chronic migraine patients. Recent evidence from mice models and a study of prolactine-associated headaches have indicated that dopamine agonists such as cabergoline might be used as a treatment of migraine.

The aim of this study is to test the hypothesis that the dopamine agonist cabergoline can be used as a treatment of chronic migraine. A randomized controlled trial of 24 patients with chronic migraine will be conducted, comparing cabergoline to placebo as an add-on medication to the patients' migraine treatment over a 12 weeks period. The primary outcome is change in migraine frequency, but also headache-related hospital contacts, and quality of life as well as prolactin levels and biomarkers of the pituitary-gonadal-axis. The results of the study will help understand the pathogenesis of migraine and might also introduce a more effective and affordable preventive migraine treatment.


Eligibility Criteria:
Inclusion Criteria:

* Migraine and more than 6 days with headache every months

Exclusion Criteria:

* Cardiac valve disease
* Hypertension
* Psychiatric disease
* Treated with dopamine receptor agonists, dopamin receptor antagonists, macrolides and itraconazole
* pregnant or breastfeeding
A Specialized Diet for the Unique Metabolic Characteristics of Peripubertal African American Girls

A diet (42% carbohydrate) specialized to the unique metabolic characteristics of peripubertal African AMerican girls (hyperinsulinemic, low insulin sensitive) will be more effective in maintaining glucose and insulin homeostasis compared to a standard diet (55% carbohydrate)


Eligibility Criteria:
Inclusion Criteria:

* African American girls aged 9-14,
* Overweight \< 90th percentile

Exclusion Criteria:

* On medications known to affect metabolism prior disease diagnosis
Female Asian Nonsmoker Screening Study

The study team propose to develop a database and biorepository of Asian female never smokers. This population is at increased risk for developing lung cancer but do not meet current lung cancer screening criteria. Study procedures will include up to 3 low-dose CT (LDCT) scans and a blood-based assay with the capability for early detection of cancer. Clinical, demographic and exposure history including possible WTC exposure will also be collected.


Eligibility Criteria:
Inclusion Criteria:

* Age 40-74 years
* Female
* Never Smoker defined as a lifetime exposure of less than 100 cigarettes
* Identify as from Asian descent, defined as having reported ancestry or race from the continent of Asia. Individuals with mixed heritage are eligible.

Exclusion Criteria:

* Prior history of lung cancer.
* Treatment for, or advisement by a physician of evidence of any cancer within the past five years, with the exceptions of non-melanoma skin cancer and most in-situ carcinomas based on PI discretion. (Treatment for, or evidence of, melanoma or in-situ bladder/transition cell carcinomas within the preceding five years renders the potential participant ineligible.)
* Participation in a cancer prevention trial.
* Present symptoms suggestive of current lung cancer, including: unexplained weight loss of over 15 pounds within the 12 months or unexplained hemoptysis.
* Medical or psychiatric condition precluding informed medical consent.
* Pneumonia or acute respiratory infection within 12 weeks of enrollment that was treated with antibiotics under physician supervision.